Monoclonal antibodies developed against PD-L1 (and PD1) block the PD-L1-PD1 interaction and inhibit antitumoral activity, which then activates the cytotoxic immune response against tumor cells (6). This evidence concerns the gene PDCD1 and neoplasm.